top of page
Secondary Tumor Patient-Derived Cells
Secondary tumor patient-derived cells (PDCs) are primary tumor cells isolated from metastatic lesions in cancer patients. These cells are cultured directly from solid tumor biopsies or fluid metastases (e.g., ascites, pleural effusion) and retain the molecular, phenotypic, and functional features of the metastatic tumor environment.

Secondary Tumor Patient-Derived Cells

$950.00Price
    • 1 mln cells/vial 
    • Post-thaw viability - ≥ 80%
    • Culture Type - monolayer or spheroid; adherent or partially adherent
    • Passage Number - P1–P5 (low-passage, minimally adapted)

    • Drug screening in metastatic tumor models

    • Resistance profiling (e.g., post-chemotherapy, post-immunotherapy)

    • Transcriptomic and proteomic biomarker discovery

    • Co-culture with immune or stromal cells

    • Patient-derived xenograft (PDX) or organoid model development

    • Cancer cell plasticity and epithelial-to-mesenchymal transition (EMT) studies

bottom of page